

May Khanna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7176159/publications.pdf>

Version: 2024-02-01

67
papers

2,331
citations

147726

31
h-index

223716

46
g-index

73
all docs

73
docs citations

73
times ranked

2742
citing authors

#	ARTICLE	IF	CITATIONS
1	Animal Models of Neurodegenerative Disease: Recent Advances in Fly Highlight Innovative Approaches to Drug Discovery. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 883358.	1.4	17
2	Aptamers Targeting Hallmark Proteins of Neurodegeneration. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 235-250.	2.0	3
3	Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. <i>Scientific Reports</i> , 2022, 12, 8140.	1.6	12
4	<i>In Silico</i> Targeting of the Long Noncoding RNA MALAT1. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 915-921.	1.3	10
5	Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells. <i>Stem Cell Reports</i> , 2021, 16, 2459-2472.	2.3	11
6	Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape. <i>RSC Chemical Biology</i> , 2021, 2, 1158-1166.	2.0	6
7	Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. <i>Science Translational Medicine</i> , 2021, 13, eabh1314.	5.8	23
8	An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties. <i>ACS Chemical Biology</i> , 2020, 15, 2854-2859.	1.6	19
9	Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2489-2510.	2.9	23
10	Abstract LB-226: Discovery of small molecule Mcl-1 and Bfl-1 inhibitors. , 2020, , .		0
11	Chemical Probes to Control RNA Function. <i>Chemical Biology</i> , 2020, , 214-246.	0.1	0
12	The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4834-4846.	1.7	20
13	¹ H, ¹⁵ N and ¹³ C backbone assignment of apo TDP-43 RNA recognition motifs. <i>Biomolecular NMR Assignments</i> , 2019, 13, 163-167.	0.4	3
14	Small Molecule Targeting TDP-43's RNA Recognition Motifs Reduces Locomotor Defects in a <i>Drosophila</i> Model of Amyotrophic Lateral Sclerosis (ALS). <i>ACS Chemical Biology</i> , 2019, 14, 2006-2013.	1.6	45
15	Structural Insights Into TDP-43 and Effects of Post-translational Modifications. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 301.	1.4	86
16	Targeting the CaV1.2-CaV2.2 interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. <i>Pain</i> , 2019, 160, 1644-1661.	2.0	30
17	Evaluation of edonepic maleate as a CRMP2 inhibitor for pain relief. <i>Channels</i> , 2019, 13, 498-504.	1.5	2
18	(α)-Hardwickic Acid and Hautriwaic Acid Induce Antinociception via Blockade of Tetrodotoxin-Sensitive Voltage-Dependent Sodium Channels. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1716-1728.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Betulinic acid, derived from the desert lavender <i>Hyptis emoryi</i> , attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels. <i>Pain</i> , 2019, 160, 117-135.	2.0	44
20	Remodeling the interactions between TDP43 and RNA for development of therapeutics for ALS. <i>FASEB Journal</i> , 2019, 33, 670.1.	0.2	0
21	Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides. <i>British Journal of Pharmacology</i> , 2018, 175, 2244-2260.	2.7	40
22	Blocking CRMP2 SUMOylation reverses neuropathic pain. <i>Molecular Psychiatry</i> , 2018, 23, 2119-2121.	4.1	47
23	A novel variant in <i>TAF1</i> affects gene expression and is associated with X-linked intellectual disability syndrome. <i>Neuronal Signaling</i> , 2018, 2, NS20180141.	1.7	16
24	A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). <i>ACS Chemical Biology</i> , 2018, 13, 3000-3010.	1.6	9
25	Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. <i>Channels</i> , 2018, 12, 219-227.	1.5	17
26	Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases Nav1.7 currents and reverses experimental neuropathic pain. <i>Pain</i> , 2018, 159, 2115-2127.	2.0	49
27	The principles of tomorrow's university. <i>F1000Research</i> , 2018, 7, 1926.	0.8	6
28	A single structurally conserved SUMOylation site in CRMP2 controls Nav1.7 function. <i>Channels</i> , 2017, 11, 316-328.	1.5	34
29	CRISPR/Cas9 editing of <i>Nf1</i> gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. <i>Pain</i> , 2017, 158, 2301-2319.	2.0	67
30	Hierarchical CRMP2 posttranslational modifications control Nav1.7 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8443-E8452.	3.3	103
31	Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. <i>Pain</i> , 2016, 157, 2124-2140.	2.0	30
32	(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. <i>Pain</i> , 2016, 157, 1448-1463.	2.0	54
33	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. <i>Molecular Neurobiology</i> , 2016, 53, 1959-1976.	1.9	50
34	A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. <i>Pain</i> , 2015, 156, 1247-1264.	2.0	71
35	Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. <i>Frontiers in Cellular Neuroscience</i> , 2015, 8, 471.	1.8	37
36	(399) A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses post-operative pain behaviors. <i>Journal of Pain</i> , 2015, 16, S75.	0.7	0

#	ARTICLE	IF	CITATIONS
37	The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 196.	1.8	38
38	Discovery and characterization of small molecules that target the GTPase Ral. <i>Nature</i> , 2014, 515, 443-447.	13.7	126
39	Small-molecule inhibition of the uPAR \hat{A} -uPA interaction: Synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2145-2155.	1.4	43
40	Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation. <i>Journal of Cell Science</i> , 2013, 126, 4262-73.	1.2	21
41	Expression and purification of functional human glycogen synthase-1 (hGYS1) in insect cells. <i>Protein Expression and Purification</i> , 2013, 90, 78-83.	0.6	12
42	Structural basis for 2 \hat{A} -phosphate incorporation into glycogen by glycogen synthase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20976-20981.	3.3	29
43	Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4760-4773.	1.4	34
44	CRMP-2 Peptide Mediated Decrease of High and Low Voltage-Activated Calcium Channels, Attenuation of Nociceptor Excitability, and Anti-Nociception in a Model of AIDS Therapy-Induced Painful Peripheral Neuropathy. <i>Molecular Pain</i> , 2012, 8, 1744-8069-8-54.	1.0	48
45	A peptide uncoupling CRMP-2 from the presynaptic Ca $^{2+}$ channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy. <i>Translational Neuroscience</i> , 2012, 3, 1-8.	0.7	36
46	NMR Studies of Protein \hat{A} -RNA Interactions. <i>Methods in Molecular Biology</i> , 2012, 831, 197-218.	0.4	2
47	Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca $^{2+}$ channel complex. <i>Nature Medicine</i> , 2011, 17, 822-829.	15.2	200
48	Targeting Multiple Conformations Leads to Small Molecule Inhibitors of the uPAR \hat{A} -uPA Protein \hat{A} -Protein Interaction That Block Cancer Cell Invasion. <i>ACS Chemical Biology</i> , 2011, 6, 1232-1243.	1.6	48
49	Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 626-636.	1.9	35
50	Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7193-7205.	2.9	32
51	Target-Specific Support Vector Machine Scoring in Structure-Based Virtual Screening: Computational Validation, In Vitro Testing in Kinases, and Effects on Lung Cancer Cell Proliferation. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 755-759.	2.5	59
52	Discovery of novel regulators of aldehyde dehydrogenase isoenzymes. <i>Chemico-Biological Interactions</i> , 2011, 191, 153-158.	1.7	33
53	Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel \hat{A} -CRMP-2 signaling complex. <i>Channels</i> , 2011, 5, 449-456.	1.5	40
54	Discovery of a Novel Class of Covalent Inhibitor for Aldehyde Dehydrogenases. <i>Journal of Biological Chemistry</i> , 2011, 286, 43486-43494.	1.6	65

#	ARTICLE	IF	CITATIONS
55	Docking to Erlotinib Off-Targets Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable in Vitro Pharmacokinetics. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 229-233.	1.3	18
56	Relative Inhibitory Potency of Molinate and Metabolites with Aldehyde Dehydrogenase 2: Implications for the Mechanism of Enzyme Inhibition. <i>Chemical Research in Toxicology</i> , 2010, 23, 1843-1850.	1.7	19
57	A systematic characterization of Cwc21, the yeast ortholog of the human spliceosomal protein SRm300. <i>Rna</i> , 2009, 15, 2174-2185.	1.6	34
58	Molecular chaperone Hsp90 stabilizes Pih1/Nop17 to maintain R2TP complex activity that regulates snoRNA accumulation. <i>Journal of Cell Biology</i> , 2008, 180, 563-578.	2.3	159
59	RNA in control. <i>Nature</i> , 2007, 447, 391-393.	13.7	7
60	Structural study of the H/ACA snoRNP components Nop10p and the 3' hairpin of U65 snoRNA. <i>Rna</i> , 2006, 12, 40-52.	1.6	34
61	Photoinduced cleavage by a rhodium complex at GÂ-U mismatches and exposed guanines in large and small RNAs. <i>Biochimie</i> , 2002, 84, 859-868.	1.3	7
62	Synthesis of a 3-methyluridine phosphoramidite to investigate the role of methylation in a ribosomal RNA hairpin. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 325-332.	1.4	13
63	Reactions of platinum(II) complexes with a DNA hairpin, d(CGCGTTGTTGCGG): structural characterization and kinetic studies. <i>Inorganica Chimica Acta</i> , 2000, 297, 145-155.	1.2	12
64	Unique structural and stabilizing roles for the individual pseudouridine residues in the 1920 region of Escherichia coli 23S rRNA. <i>Nucleic Acids Research</i> , 2000, 28, 2075-2083.	6.5	83
65	Thermodynamics of RNA hairpins containing single internal mismatches. <i>Nucleic Acids Research</i> , 1999, 27, 1118-1125.	6.5	34
66	Modeling of Pontocerebellar Hypoplasia Type 1B and Chemical Mimicry in Patient-Derived Neural Stem Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
67	Small Molecules Targeting RIPK3/MLKL Interactions Disrupt Necroptosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0